Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Feb 23 04:00PM ET
1.30
Dollar change
+0.14
Percentage change
12.07
%
Index- P/E- EPS (ttm)-1.76 Insider Own16.30% Shs Outstand225.41M Perf Week26.21%
Market Cap293.03M Forward P/E- EPS next Y-0.78 Insider Trans0.64% Shs Float188.67M Perf Month60.55%
Income-187.43M PEG- EPS next Q-0.21 Inst Own79.49% Short Float8.86% Perf Quarter71.17%
Sales0.00M P/S- EPS this Y54.12% Inst Trans11.66% Short Ratio12.03 Perf Half Y23.81%
Book/sh0.46 P/B2.80 EPS next Y37.66% ROA-55.83% Short Interest16.72M Perf Year-26.55%
Cash/sh1.46 P/C0.89 EPS next 5Y5.20% ROE-232.88% 52W Range0.45 - 1.91 Perf YTD42.47%
Dividend Est.- P/FCF- EPS past 5Y-92.43% ROI-61.33% 52W High-31.94% Beta1.65
Dividend TTM- Quick Ratio8.07 Sales past 5Y0.00% Gross Margin- 52W Low187.29% ATR (14)0.11
Dividend Ex-Date- Current Ratio8.07 EPS Y/Y TTM39.09% Oper. Margin0.00% RSI (14)74.54 Volatility16.59% 11.83%
Employees178 Debt/Eq2.06 Sales Y/Y TTM- Profit Margin- Recom1.80 Target Price6.09
Option/ShortYes / Yes LT Debt/Eq1.92 EPS Q/Q68.14% Payout- Rel Volume1.00 Prev Close1.16
Sales Surprise- EPS Surprise18.13% Sales Q/Q- EarningsNov 09 BMO Avg Volume1.39M Price1.30
SMA2039.22% SMA5040.09% SMA20028.76% Trades Volume1,387,847 Change12.07%
Date Action Analyst Rating Change Price Target Change
Jul-27-23Downgrade UBS Buy → Neutral $8 → $1.25
Mar-07-23Downgrade Raymond James Outperform → Mkt Perform
Mar-01-23Initiated Guggenheim Neutral
Dec-07-22Downgrade SMBC Nikko Outperform → Neutral $3
Dec-07-22Downgrade JP Morgan Neutral → Underweight
Dec-07-22Downgrade Barclays Overweight → Equal Weight $18 → $2
Oct-20-22Initiated Goldman Buy $22
Sep-21-22Initiated JP Morgan Neutral $17
Sep-19-22Initiated Wedbush Outperform $24
Apr-18-22Initiated Raymond James Outperform $19
Jan-31-24 02:23PM
Jan-22-24 10:53AM
Jan-08-24 04:01PM
Dec-13-23 04:01PM
Dec-05-23 04:01PM
07:01AM Loading…
07:01AM
Nov-29-23 07:01AM
Nov-09-23 08:11AM
07:41AM
07:31AM
Oct-23-23 10:08AM
Oct-03-23 04:08PM
Sep-07-23 07:44AM
Aug-28-23 08:20AM
Aug-08-23 04:41PM
04:01PM Loading…
04:01PM
Jul-24-23 04:16PM
Jul-20-23 07:56AM
Jun-23-23 06:24AM
May-18-23 07:05AM
May-13-23 08:15AM
May-09-23 04:13PM
04:01PM
Apr-04-23 12:38PM
Mar-17-23 07:46AM
07:31AM
Mar-07-23 03:37PM
Mar-03-23 11:40AM
Feb-01-23 04:25PM
Jan-04-23 12:00PM
09:35AM Loading…
09:35AM
Dec-26-22 09:41AM
Dec-06-22 01:19PM
10:00AM
08:19AM
07:15AM
Nov-17-22 02:37PM
Nov-08-22 12:00PM
Nov-03-22 04:01PM
Oct-24-22 08:30AM
Aug-29-22 08:11AM
Aug-09-22 08:01AM
Jul-21-22 06:21PM
Jul-20-22 11:33AM
Jul-19-22 12:00PM
09:46AM
Jul-18-22 09:55AM
Jul-13-22 07:15AM
Jun-09-22 08:30AM
May-26-22 09:55AM
May-23-22 09:55AM
May-10-22 04:01PM
May-06-22 12:20PM
Apr-25-22 07:29AM
Mar-03-22 04:01PM
Feb-28-22 07:01AM
Jan-02-22 08:47AM
Nov-08-21 04:01PM
Nov-02-21 04:01PM
Oct-11-21 08:36AM
Oct-07-21 04:01PM
Oct-03-21 10:45AM
Sep-21-21 08:31AM
Aug-09-21 04:01PM
Aug-02-21 04:01PM
Jul-21-21 05:16AM
Jul-17-21 05:47AM
Jul-07-21 07:01AM
Jun-21-21 04:01PM
Jun-14-21 04:01PM
May-06-21 07:31AM
Apr-20-21 07:50AM
Apr-16-21 07:55AM
Feb-25-21 07:31AM
Feb-19-21 08:01AM
Feb-04-21 07:05AM
Jan-18-21 03:05AM
Dec-19-20 03:54PM
Dec-11-20 05:00PM
Dec-07-20 07:03AM
Nov-16-20 07:01AM
Nov-10-20 04:01PM
02:30PM
08:00AM
Nov-06-20 07:07AM
07:03AM
Oct-13-20 03:02PM
07:04AM
Oct-12-20 08:07AM
Oct-09-20 08:01AM
Sep-30-20 08:38AM
Sep-10-20 07:07AM
Sep-07-20 11:00AM
Sep-01-20 04:30PM
Aug-11-20 04:01PM
Aug-05-20 08:31AM
Jul-22-20 12:55PM
08:12AM
Jul-03-20 06:27PM
Jun-08-20 09:00AM
Gossamer Bio, Inc. engages in discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. Its primary product candidate, GB001, is intended for the treatment of moderate-to-severe eosinophilic asthma and other allergic conditions. The company was founded by Faheem Hasnain and Sheila Gujrathi on October 25, 2015 and is headquartered in San Diego, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Milligan SandraDirectorNov 15Buy0.7932,00025,21332,000Nov 17 04:01 PM
Giraudo BryanCOO/CFONov 13Buy0.56200,000112,880380,010Nov 14 06:24 PM
Aranda RichardChief Medical OfficerJun 22Sale1.291,8142,340197,574Jun 26 04:01 PM
Giraudo BryanCOO/CFOApr 04Buy1.0255,00056,094125,990Apr 05 04:26 PM
Hasnain FaheemPresident & CEOMar 22Buy1.14440,500503,5804,495,897Mar 22 05:14 PM
Hasnain FaheemPresident & CEOMar 21Buy1.20269,389322,3244,055,397Mar 22 05:14 PM
Hasnain FaheemPresident & CEOMar 20Buy1.03168,683174,4863,786,008Mar 22 05:14 PM
Giraudo BryanCOO/CFOMar 20Buy0.9750,00048,43570,990Mar 22 05:17 PM
Christian WaageEVP, Tech Ops and AdminMar 20Buy1.2018,50022,14432,388Mar 22 05:19 PM
Peterson CarynEVP, Regulatory AffairsMar 16Sale1.107,5648,30553,851Mar 20 09:19 AM
Aranda RichardChief Medical OfficerMar 16Sale1.107,5638,304199,388Mar 20 09:21 AM
Carter LauraChief Scientific OfficerMar 16Sale1.106,0296,62076,263Mar 20 09:22 AM